All In MedTech

Device Trial Radar · NCT05495698

Triple Therapy Convenience by the Use of One or Multiple Inhalers and Digital Support in Chronic Obstructive Pulmonary Disease

Last checked: Nov 19, 2026Latest source record: Aug 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Dec 13, 2022

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Franciscus GasthuisAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 10, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated device
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TRICOLON is an investigator initiated, prospective, interventional, open-label, randomized, real-world, multi-centre, 3-arms study in the Netherlands. The primary objective is to investigate in COPD patients if single-inhaler triple therapy (SITT) is superior to multi-inhaler triple therapy (MITT) in terms of adherence to inhaled corticosteroids (ICS) therapy and to investigate if SITT with e-health support is superior to MITT and SITT without e-health support.

Conditions

  • Copd
  • Adherence, Medication

Interventions

  • single-inhaler triple therapy (Trimbow)Drug

    Patients in the intervention group will receive the triple therapy in one inhaler in stead of multiple inhalers. The actual medication is the same.

  • E-health application: Curavista app & FindAir e-deviceDevice

    Patients in intervention group 2 will receive Trimbow and will use the health app of Curavista and the smart-inhaler of FindAir

  • multi-inhaler triple therapy (Qvar + Bevespi)Drug

    Patients in the intervention group will receive the triple therapy in multiple inhalers. The actual medication is the same.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adherence to ICS therapyTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Franciscus Gasthuis & Vlietland

    Rotterdam, South Holland, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.